Research Letters
3 Results
- Research Letter
Outcomes of first cases of DMEK at a Canadian university hospital centre
Canadian Journal of OphthalmologyVol. 57Issue 3p214–215Published online: June 10, 2021- Michael Marchand
- Jonathan El-Khoury
- Mona Harissi-Dagher
- Marie-Claude Robert
Cited in Scopus: 1Descemet membrane endothelial keratoplasty (DMEK) provides better visual outcomes and lower rejection rates than Descemet stripping automated endothelial keratoplasty (DSAEK).1,2 However, steep learning curves, higher rebubbling rates, and failure risks have been noted.3–6 This study aimed to report and analyze the outcomes of the first DMEK cases in our university-based centre. - Research Letter
Features and management of strabismus from skull base chordoma
Canadian Journal of OphthalmologyVol. 57Issue 2p137–141Published online: June 4, 2021- Zoya Chaudhry
- Georges Nassrallah
- Michael Flanders
Cited in Scopus: 0Chordomas are rare neoplasms derived from primitive notochordal remnants that almost always develop from bone and that can occur anywhere along the spinal axis from the clivus to the sacrum.1,2 Fifty percent of these tumours occur in the sacrococcygeal area, 35% arise from the clivus, and 15% arise elsewhere in the vertebral column.3 Skull base chordomas account for 0.3%–1.0% of intracranial tumours.4 Chordomas can develop at any age, but they typically affect patients in the third, fourth, and fifth decades of life. - Research Letter
Clinical course and poor prognostic factors of Vogt–Koyanagi–Harada disease in a tertiary uveitis clinic
Canadian Journal of OphthalmologyVol. 57Issue 2p142–144Published online: May 10, 2021- Arash Maleki
- Stephen D. Anesi
- Sydney Look-Why
- Soheila Asgari
- Ambika Manhapra
- C. Stephen Foster
Cited in Scopus: 1Vogt–Koyanagi–Harada (VKH) disease is an autoimmune inflammatory disorder that can present with ophthalmic, neurologic, auditory, and dermatologic manifestations.1 In this study, we investigated possible factors that might subsequently result in poor visual function.